Bright Minds Biosciences is a brand-new company record, and its full research profile isn't ready yet.
brightmindsbio.comCrawled Oct 28, 2026
We are developing more effective next-generation neuropsychiatric therapeutics for Patients in Need. Targeting patients with major depressive disorder.
Bright Minds Biosciences a leading Pharmaceutical company has a unique pipeline of 5-HT2C agonists being evaluated for the treatment of epilepsy and more.
Canada’s Health Minister Patty Hajdu approved psychedelic drug use for four terminally ill patients under Section 56 of the Controlled Drugs and Substances Act.
Thomas Hartle, a 52-year-old IT technician from Saskatoon, began using medicinal cannabis after never trying drugs before.
Bright Minds’ compound significantly reduced fentanyl intake in an animal model of opioid abuse.
Bright Minds’ compound reduced binge eating in rats, showing potential for human efficacy.
Dennis J. Dlugos is Professor of Neurology and Pediatrics at the University of Pennsylvania and Director of the Pediatric Epilepsy Program at Children’s Hospital of Philadelphia.
Dr. Jo Sourbron specializes in genetic epilepsy and clinical trials for drug-resistant epilepsy at University Hospitals of Ghent and University of Leuven.
Jacqueline French is a professor of Neurology at NYU Grossman School of Medicine and founder of the Epilepsy Study Consortium.
Bright Minds employs neuroscientists, drug developers, and top scientists specializing in psychedelic compounds.
Bright Minds collaboration with the National Institutes of Health and other medical universities to amplify the understanding of mental and neurological disorders.
Bright Minds uses modern tools to develop innovative treatments for mental health issues.
Bright Minds Biosciences focuses on neuropsychiatry, pain, and epilepsy treatments.
Bright Minds Bio a pharmaceutical company. Our team of neuroscientists, drug developers, and physicians tackling the big problems in mental health and neurology.
Bright Minds Biosciences Inc. outlines its privacy policy, effective July 15, 2026, and last updated September 30, 2026.
Bright Minds Biosciences Inc. explains how it collects, uses, and protects personal information in its privacy policy, effective July 15, 2026, and last updated October 3, 2026.
Bright Minds Biosciences Inc. outlines website terms of use, effective October 2026.
Bright Minds Biosciences Inc. provides terms of use for its websites, including brightmindsbio.com.